BioMedNewsBreaks Archive - Page 113 of 246

MondayMay 22, 2023 1:44 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Looking to Complement Core Focus with CDMO Offering

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company aims to complement its core focus, nanosized antibody (“NanoAb”) pipeline development, with a comprehensive CDMO (contract development and manufacturing organization) offering. “With significant experience including developing its previous flu vaccine candidate, BiondVax intends to share its expertise, human resources and facilities with pharma companies to develop and manufacture their drug candidates for preclinical use as well as clinical testing,” a recent article reads. “BiondVax’s CDMO services cover aseptic fill and finish, upstream and…

MondayMay 22, 2023 11:17 am

BioMedNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Releases Details of Common Share Offering

Universal Ibogaine (TSX.V: IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, has announced an offering of up to 66,666,667 shares. The shares will be offered $0.03 per share, which could result in approximately $2 million in gross proceeds. According to the announcement, each unit will include one common share and a one-half common share purchase warrant, with each whole warrant giving the holder the right to purchase an additional UI common share at $0.06 per share; that right will be available for up to one year after the offering closes. UI anticipates using the offering…

FridayMay 19, 2023 12:37 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO Featured in Upcoming Water Tower Research Fireside Chat

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be represented at an upcoming Water Tower Research Fireside Chat Series. The company announced that CEO Eric A. Adams will be the featured speaker at the May 23, 2023, fireside chat; the event is slated to begin at 1 p.m. ET. During the chat, Adams will present an overview of the company’s pharmaceutical development pipeline. He will also discuss subsidiary BayMedica and its anticipated impact on InMed's growth as well as upcoming catalysts for the company. A replay of the…

ThursdayMay 18, 2023 1:26 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces FDA 510(k) Submission of HeartBeam AIMIGo(TM) Solution

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for its HeartBeam AIMIGo(TM) System. The HeartBeam AIMIGo System is a personal, portable and easy-to-use VECG solution to assist patients and their clinicians in assessing cardiac symptoms. The breakthrough solution employs a reusable, credit card-sized, VECG recording device and cloud-based software to deliver critical data in real-time outside of a medical setting. “The 510(k) submission of our HeartBeam AIMIGo…

TuesdayMay 16, 2023 1:23 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company has been awarded approximately C$2.81 million in an arbitration settlement. An InvestmentPitch Media video provides additional information about this news and the company. The video is available for viewing on InvestmentPitch and YouTube. To view the full press release, visit https://ibn.fm/2G1zT About FSD Pharma Inc. FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, a wholly owned…

TuesdayMay 16, 2023 12:58 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q1 2023 Financial Results, Business Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting its financial results for the first quarter ended March 31, 2023; the report also noted key business updates. Highlights of the report indicate R&D expenses for quarter totaled $2 million with marketing, general and administrative expenses for the quarter reaching $1.2 million and total operating expenses coming in at $3.2 million, compared with $2.6 for same period in 2022. The report noted financial (loss) income for the quarter totaling $(0.3) million compared with $0.14 million for…

MondayMay 15, 2023 3:31 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023, which ended March 31, 2023. “The third quarter of fiscal year 2023 was an important period for InMed, as we achieved several key milestones across our different business segments, including completing enrollment in our phase 2 clinical trial for epidermolysis bullosa, marking the first time cannabinol (‘CBN’) has completed a phase 2 clinical trial. We look forward to the data read out during 3Q and will then…

MondayMay 15, 2023 2:38 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Reports on Q1 2023 Financial Results

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has release a report on its first-quarter revenues for the period ended March 31, 2023. The company reported revenues for the quarter totaled $1,121,676, compared to $721,629 in Q1 2022. Operating expenses for the quarter came in at $1,496,537, compared to $2,978,933 for the same period in 2022, and net losses totaled $1,308,174 for the three months, compared to $2,919,775 for the same period in 2022. “I am thrilled with our team's progress this quarter, demonstrating substantial revenue growth and a significant reduction in operating expenses,”…

MondayMay 15, 2023 2:25 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2023 Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended March 31, 2023. In addition, the company provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer. “Over the course of the first quarter, our team has continued its flawless operational execution of our potentially pivotal study witnessed by our recent enrollment update boasting 100 patients now dosed in this global clinical…

MondayMay 15, 2023 1:31 pm

BioMedNewsBreaks – Progressive Care Inc. (RXMD) Releases Record breaking Q1 2023 Financial Results

Progressive Care (OTCQB: RXMD), a personalized healthcare services and technology provider, is reporting its financial results for the first quarter ended March 31, 2023. According to the report, the company saw record quarterly revenue; the report showed a $11.4 million revenue for the first quarter, a 13% increase from the first quarter ended March 31, 2022. Other highlights include total pharmacy revenue increasing by $1.3 million, or 13%; prescription revenue increased by $1.8 million, or 21%, to total $10.4 million during the first quarter of 2023; 340B contract revenue for the quarter was $1.6 million, an increase of $1.2 million; gross…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Looking to Complement Core Focus with CDMO Offering

BioMedNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Releases Details of Common Share Offering

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO Featured in Upcoming Water Tower Research Fireside Chat

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces FDA 510(k) Submission of HeartBeam AIMIGo(TM) Solution

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q1 2023 Financial Results, Business Update

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Reports on Q1 2023 Financial Results

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2023 Results, Corporate Update

BioMedNewsBreaks – Progressive Care Inc. (RXMD) Releases Record breaking Q1 2023 Financial Results

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search